May 16-19, 2004, Crystal Gateway Marriott, Arlington, VA

POSTER PRESENTATIONS-SESSION I

ARTHRITIS

ARTHRITIS-Clinical Outcomes Studies 

PAR1
RHEUMATOID ARTHRITIS IMPACT OF DISEASE AND DRUG THERAPY
Franic DM¹, Kotzan J¹, Fagan SC¹, Grauer D^2
1The University of Georgia, Athens, GA, USA; ²The University of Kansas, Kansas City, KS, USA
 

PAR2
INFLIXIMAB DOSING PATTERNS IN RHEUMATOLOGY PRACTICES
Hendricks D, Callegari P, Ziskind M
Centocor Inc, Malvern, PA, USA

ARTHRITIS-Cost Studies
 

PAR3
ECONOMIC EVALUATION OF SELF-INJECTION VS AMBULATORY CARE OF ANTI-RHEUMATOID BIOLOGICS (ETANERCEPT) IN JAPAN
Igarashi A¹, Fukuda T¹, Tsutani K¹, Miyasaka N^2
1University of Tokyo, Bunkyo, Tokyo, Japan; ²Tokyo Medical and Dental University, Tokyo, Bunkyo-ku, Japan  

PAR4
COST-EFFECTIVENESS OF TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS AS FIRST-LINE AGENTS IN RHEUMATOID ARTHRITIS
Spalding JR, Hay JW
University of Southern California, Los Angeles, CA, USA  

PAR5
COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRA^TM) IN THE TREATMENT OF US PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
Bansback N¹, Brennan A¹, Sengupta N^2
1University of Sheffield, Sheffield, South Yorkshire, United Kingdom; ²Abbott Laboratories, Abbott Park, IL, USA  

PAR6
COST-EFFECTIVENESS OF TREATMENT STRATEGIES FOR RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE
Patel VD, Hay J
University of Southern California, Los Angeles, CA, USA  

ARTHRITIS -Quality Of Life/Patient-Reported Outcomes/Patient Preference Studies 

PAR7
ASSESSMENT OF PATIENT-REPORTED OUTCOMES AMONG OSTEOARTHRITIC PATIENTS
Gandra SR, Lawrence LW
The University of Louisiana at Monroe, Monroe, LA, USA  

PAR8
THE RELATIONSHIP BETWEEN GASTROINTESTINAL SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE IN KOREAN PATIENTS WITH RHEUMATIC DISEASES
Bae SC¹, Kim S², Uhm WS^1
1Hanyang University, Seoul, Korea, Seoul, South Korea; ²Pochon CHA University, SeongNam, South Korea  

PAR9
HEALTH RELATED QUALITY OF LIFE OF CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS PATIENTS RECEIVING FENTANYL TRANSDERMAL SYSTEM
Hamed A¹, Huang YH¹, Lee A¹, Miller DR¹, Ren SX¹, Iqbal U¹, Vallow S², Schein J², Kazis L^1
1Boston University, Boston, MA, USA; ²Janssen Pharmaceutica Products, Titusville, NJ, USA  

PAR10
IMPROVING THE SENSITIVITY OF PHYSICAL FUNCTION MEASURES IN RHEUMATOID ARTHRITIS: USE OF ITEM RESPONSE THEORY IN PATIENTS TREATED WITH ABATACEPT (CTLA4IG)
Martin M¹, Emery P², Kosinski M¹, Ware J¹, Li T³, Williams R⁴, Maclean R³, Bjorner J^1
1Quality Metric, Inc, Lincoln, RI, USA; ²University of Leeds, Leeds, United Kingdom; ³Bristol-Myers Squibb, Princeton, NJ, USA; ⁴Bristol-Myers Squibb, Brussels, Belgium

PAR11
REVALIDATION OF THE CEDARS-SINAI RHEUMATOID ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA) SHORT FORM INSTRUMENT
Chiou CF¹, Sherbourne C², Cornelio IL³, Lubeck D³, Paulus H⁴, Dylan M¹, Weisman M^5
1Zynx Health, A Cerner Company, Beverly Hills, CA, USA; ²RAND Corporation, Santa Monica, CA, USA; ³Amgen, Inc, Thousand Oaks, CA, USA; ⁴University of California, Los Angeles, Los Angeles, CA, USA; ⁵Cedars-Sinai Health System, Los Angeles, CA, USA  

PAR12
PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR VIOXX® AS A TREATMENT FOR OSTEOARTHRITIS RELATIVE TO NSAIDS
Tilden D¹, Mernagh P², FitzGerald P², Adams J², Mark S³, van Bavel J³, Davey P^4
1M-TAG Pty Ltd., London, United Kingdom, England; ²M-TAG Pty Ltd Australia, Chatswood West, NSW, Australia; ³Merck Sharpe and Dohme, Granville, NSW, Australia; ⁴Medical Technology Assessment Group, Chatswood West, NSW, Australia  

PAR13
BURDEN OF OSTEOARTHRITIS AND ITS TREATMENT ON PATIENTS
Chang J¹, Kauf T², Mahajan S², Reed S³, Friedman J², Omar M¹, Kahler K¹, Schulman K^2
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; ²Duke University, Durham, NC, USA; ³Duke Clinical Research Institute  

PAR14
CONTRIBUTION OF PAIN, SITE OF PAIN AND NUMBER OF JOINTS AFFECTED ON PRODUCTIVITY LOSS AMONG WORKERS AND NON-WORKERS WITH OSTEOARTHRITIS
Mahajan S¹, Kauf T¹, Chang J², Omar M², Kahler K², Schulman K^1
1Duke University, Durham, NC, USA; ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA  

PAR15
ETHNIC VARIATIONS IN PREFERENCE FOR TOTAL KNEE REPLACEMENT IN PATIENTS WITH OSTEOARTHRITIS
Suarez-Almazor M¹, Souchek J¹, Kelly PA², Byrne M³, Richardson M¹, Pak C^2
1Baylor College of Medicine and Houston Center for Quality of Care & Utilization Studies, Houston, TX, USA; ²Baylor College of Medicine and Houston Center for Quality of Care and Utilization Studies, Houston, TX, USA; ³University of Pittsburgh, Pittsburgh, PA, USA 

PAR16
TRENDS IN THE USE OF PATIENT REPORTED OUTCOMES IN OSTEOARTHRITIS CLINICAL TRIALS AND SUBSEQUENT PRODUCT LABELS
Stafkey DR¹, Coombs JH^2
1University of Michigan/ Pfizer, Ann Arbor, MI, USA; ²Pfizer Inc, Ann Arbor, MI, USA

PAR17
CHARACTERIZATION OF THE TREATMENT OF RHEUMATOID ARTHRITIS FOR PATIENTS PRESCRIBED TUMOR NECROSIS FACTOR-ALPHA INHIBITORS
Stockl K¹, Jarrar M¹, Tandon N^2
1Prescription Solutions, Costa Mesa, CA, USA; ²Centocor, Inc, Malvern, PA, USA  

ARTHRITIS - Health Policy Studies 

PAR18
RACIAL DISPARITIES IN PRESCRIBING OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS OVER OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN A MEDICAID MANAGED CARE POPULATION
Shaya FT, Blume SW, Blanchette CM, Mullins CD
University of Maryland, Baltimore, MD, USA  
 

CANCER 

CANCER -Clinical Outcomes Studies 

PCN1
EPOETIN ALFA AND DARBEPOETIN ALFA ANEMIA TREATMENT OUTCOMES IN CANCER PATIENTS FROM A VA PERSPECTIVE
Papatheofanis FJ¹, Fastenau JM², Chiang T¹, Piech CT^2
1Aequitas, Carlsbad, CA, USA; ²Ortho Biotech Products, L.P, Bridgewater, NJ, USA

PCN2
IMPACT OF CHEMOTHERAPY- INDUCED DIARRHEA ON MANAGEMENT PATTERNS AND RESOURCE UTILIZATION AMONG CANCER PATIENTS: RESULTS FROM A MULTI-SITE STUDY
Arnold R¹, Gabrail N², Raut M³, Kim R¹, Sung J³, Gause D³, Zhou Y^1
1Pharmacon International, Inc, New York, NY, USA; ²Nashat Y. Gabrail, Canton, OH, USA; ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA  

PCN3
POTENTIAL IMPACT OF WANING OF VACCINE-INDUCED IMMUNITY AGAINST HUMAN PAPILLOMAVIRUS 16/18
Goldie S¹, Kohli M², Grima D², Weinstein M¹, Wright T³, Bosch F⁴, Franco E^5
1Harvard School of Public Health, Boston, MA, USA; ²Innovus Research Inc, Burlington, ON, Canada; ³Columbia University, New York, NY, USA; ⁴Institut Catala D'Oncologia, Barcelona, Spain; ⁵McGill University, Montreal, QC, Canada  

PCN4
TECHNOLOGY ADVANCES AND TREATMENT PATTERN VARIATIONS IN ONCOLOGY: EVIDENCE FROM USE OF CPT-11 IN ELDERLY METASTATIC COLORECTAL CANCER PATIENTS.
Shih YCT
The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

PCN5
ANALYSIS OF OVER 2,400 MODERN PHASE I CANCER TRIALS: COMPOSITION, OUTCOMES, AND USE OF SURROGATE ENDPOINTS
Roberts TG¹, Goulart BH¹, Stallings SC², Squitieri L², Chabner BA¹, Finkelstein SN², Clark JW^1
1Massachusetts General Hospital, Boston, MA, USA; ²Massachusetts Institute of Technology, Cambridge, MA, USA  

PCN6
FACTORS INFLUENCING PHYSICIAN RECOMMENDATION FOR IMATINIB MESYLATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
Iyer SS, Doucette WR
University of Iowa, Iowa City, IA, USA  

CANCER -Cost Studies 

PCN7
TRENDS IN CHEMOTHERAPY USE, OUTCOMES, AND COST FOR PATIENTS WITH ADVANCED NONSMALL LUNG CANCER: EVIDENCE FROM SEER-MEDICARE
Ramsey SD, Etzioni RD, Howlader N, Abullarade J
Fred Hutchinson Cancer Research Center, Seattle, WA, USA  

PCN8
OUTCOMES AND COSTS OF SURROGATE END-POINTS (SES) AND BIOMARKERS IN PHASE I ONCOLOGY CLINICAL TRIALS
Goulart BHL, Roberts TG, Liu Y, Clark JW
Massachusetts General Hospital, Boston, MA, USA

PCN9
COST EFFECTIVENESS OF ADDING BISPHOSPHONATES TO THE NON-SURGICAL ANDROGEN DEPRIVATION THERAPY FOR FRACTURE REDUCTION IN PATIENTS WITH NON-METASTATIC PROSTATE CANCER
Phatak HM, Thomas III J
Purdue University, West Lafayette, IN, USA

PCN10
THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY (MAL-PDT) FOR BASAL CELL CARCINOMA
Orme ME, Howard P
Heron Evidence Development, Letchworth, Herts, United Kingdom

PCN11

COST-EFFECTIVENESS ANALYSIS OF DOSE-DENSE CHEMOTHERAPY WITH FILGRASTIM AS POSTOPERATIVE ADJUVANT TREATMENT OF BREAST CANCER
Yu AP, Hay JW
University of Southern California, Los Angeles, CA, USA

PCN12

ECONOMIC BURDEN OF PANCREATIC CANCER AND TREATMENT FAILURE
Chang S¹, Long S¹, Kutikova L², Bowman L², Crown WH^3
1Medstat, Washington, DC, USA; ²Eli Lilly and Company, Indianapolis, IN, USA; ³The MEDSTAT Group, Cambridge, MA, USA

PCN13

AN ECONOMIC ANALYSIS OF RADIATION VERSUS RADIATION PLUS GOSERELIN IN THE TREATMENT OF LOCALLY ADVANCED PROSTATE CANCER
Taylor MD
University of Florida, Gainesville, FL, USA

PCN14
WITHDRAWN

PCN15

DIRECT MEDICAL COSTS OF MANAGING TOXICITIES RELATED TO TAXANE THERAPY FOR METASTATIC BREAST CANCER IN THE UNITED STATES
Bramley TJ, Vishalpura TT, Nightengale BS
Applied Health Outcomes, Palm Harbor, FL, USA

PCN16

ECONOMIC BURDEN OF PROSTATE CANCER AMONG HOSPITALIZED PATIENTS
Atkins E, Xiao H
Florida Agricultural & Mechanical University, Tallahassee, FL, USA

PCN17

THE HEALTH CARE COST OF SMOKING IN CANADA
Petit P¹, Cremieux P², Ouellette P^3
1Groupe d’analyse, inc, Montreal, QC, Canada; ²Analysis Group, Boston, MA, USA; ³Universite’ du Quebec a Montreal, Montreal, QC, Canada

PCN18

COST ANALYSIS OF LUNG CANCER TREATMENT IN TAIWAN
Yang CH, Chang CJ
National Taiwan University Hospital, Taipei, Taiwan

PCN19

THE COST-EFFECTIVENESS ANALYSIS RECOMBINANT HUMAN ERYTHROPOIETIN GROWTH FACTORS VS. TRANSFUSION IN CHEMOTHERAPY CANCER PATIENTS
Tonnu IQ, Hay J
USC School of Pharmacy, Los Angeles, CA, USA

PCN20

PRELIMINARY ECONOMIC ANALYSIS OF THE AMERICAN CANCER SOCIETY GUIDELINES FOR MAMMOGRAPHY SCREENING IN AVERAGE-RISK WOMEN UNDER 70 YEARS OF AGE
Zammit D, Hay J
University of Southern California, Los Angeles, CA, USA

PCN33
WEEKLY EPOETIN ALFA (EPO QW) FOR CHEMOTHERAPY-RELATED ANEMIA IS COST-EFFECTIVE COMPARED TO DARBEPOETIN ALFA ADMINISTERED BY EVERY 2-WEEK (DARB Q2W) OR FRONT LOADING (DARB FL) SCHEDULES Rosberg J¹, Duh M1, Cremieux P¹, McKenzie S², Fastenau JM², Piech CT² 1Analysis Group, Bridgewater, NJ, USA; ²Ortho Biotech Products, L.P, Bridgewater, NJ, USA
 

CANCER -Quality Of Life/Patient Preferences

PCN21

SHORT-TERM PSYCHOSOCIAL COUNSELING FOR PATIENTS WITH NEWLY-DIAGNOSED PROSTATE CANCER
Sadetsky N¹, Kneier A¹, Latini DM¹, Knight S², Loi J¹, Carroll PR^1
1University of California, San Francisco, CA, USA; ²San Francisco VA Medical Center, San Francisco, CA, USA

PCN22

THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE CORE QUESTIONNAIRE (EORTC QLQ-C30): VALIDATION OF ENGLISH VERSION IN SINGAPORE
Xie F, Luo N, Li S
National University of Singapore, Singapore, Singapore

PCN23

XEROSTOMIA SYMPTOMS: A NEWLY DEVELOPED PATIENT REPORTED OUTCOMES QUESTIONNAIRE
Colwell HH¹, Pritchard ML¹, Hill JC¹, Sneeringer RK¹, Miller DP¹, Calhoun EA^2
1Ovation Research Group, Highland Park, IL, USA; ²Northwestern University, Chicago, IL, USA

PCN24

QUALITY OF LIFE OF NEWLY DIAGNOSED PROSTATE CANCER PATIENTS IN A PUBLIC VS. PRIVATE SETTING
Jayadevappa R¹, Chhatre S, Fomberstein K, Johnson KJ, Rosner A, Bloom BS, Malkowicz SB
University of Pennsylvania, Philadelphia, PA, USA

PCN25

CASE-MATCHED CONTROLLED STUDY SHOWS MEN PREFER PROSTATE BRACHYTHERAPY TO CONFORMAL RADIATION THERAPY
Kulkarni S¹, Hanlon A¹, Konski A², Pollack A², Horwitz E², Raysor S¹, Bruner DW^1
1Fox Chase Cancer Center, Cheltenham, PA, USA; ²Fox Chase Cancer Center, Phila, PA, USA

PCN26

ARE HEALTH STATES “TIMELESS”? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION USING A REPEATED MEASURES DESIGN
Franic DM¹, Gafni A^2
1The University of Georgia, Athens, GA, USA; ²McMaster University, Hamilton, ON, Canada

CANCER -Health Policy Studies 

PCN27
HE BREAST CANCER SCREENING RATES OF GEORGIA MEDICAID RECIPIENTS
Chen H, Kotzan JA, Martin BC
¹The University of Georgia, Athens, GA, USA

CANCER -Methods 

PCN28
GAPS IN COLORECTAL CANCER OUTCOMES RESEARCH
Ye X¹, Schommer JC¹, Castellanos JW¹, Sanchez LD¹, Wagner S^2
1University of Minnesota, Minneapolis, MN, USA; ²Pfizer Corporation, New York, NY, USA  

PCN29

MEASURING CHEMOTHERAPY EFFECTIVENESS IN NATURALISTIC SETTINGS: THE THREE FACES OF RELATIVE DOSE INTENSITY
Kilgore KM, Zdanis MR
Cetus Group, LLC, Timonium, MD, USA

PCN30

USING THE DIFFERENCE IN DIFFERENCE METHOD TO UNDERSTAND OUTCOMES IN PROSTATE CANCER
Lee WC¹, Pashos CL², Brandman J³, Wang Q¹, Botteman M^1
1Abt Associates Inc, Bethesda, MD, USA; ²Abt Associates Inc, Cambridge, MA, USA; ³Novartis Pharmaceutical, Florham Park, NJ, USA

PCN31

WEIGHT OR NOT TO WEIGHT?
Baser O¹, Given C^2
1The MEDSTAT Group, Ann Arbor, MI, USA; ²Michigan State University, East Lansing, MI, USA  

PCN32
CENSORED MEDICAL COST ESTIMATION
Baser O¹, Gardiner J², Bradley C², Given C^2
1The MEDSTAT Group, Ann Arbor, MI, USA; ²Michigan State University, East Lansing, MI, USA

CHRONIC OBSTRUCTIVE PULMONARY DISEASE 

CHRONIC OBSTRUCTIVE PULMONARY DISEASE -Clinical Outcomes Studies

PCO1
SMOKING BEHAVIOR AMONG COPD PATIENTS, SASKATCHEWAN CANADA
Curkendall SM¹, Goehring E², Stang MR³, de Luise C⁴, Lanes S⁵, Jones JK^6
1Health care Data Analysis, Vienna, VA, USA; ²The Deggge Group; ³Saskatchewan Health, Saskatchewan, Canada; ⁴Pfizer, Inc; ⁵Boehringer-Ingelheim Pharmaceuticals, Inc., Ingeheim, Germany; ⁶The Degge Group, Ltd, Arlington, VA, USA

PCO2
IMPACT OF ANEMIA ON HOSPITALIZATION AND MORTALITY IN ELDERLY PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CHRONIC KIDNEY DISEASE
Coley KC, Saul MI, Kirisci L, Smith RB
University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA  

CHRONIC OBSTRUCTIVE PULMONARY DISEASE -Cost Studies 

PCO3
ESTIMATING COST-EFFECTIVENESS OF INHALED CORTICOSTEROIDS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE PRESENCE OF MISSING DATA
Gagnon YM¹, Briggs AH², Levy AR³, Spencer S⁴, Bale G⁵, Spencer MD⁶, Burge PS^5
1Occam Research & Consulting Inc, Vancouver, BC, Canada; ²University of Oxford, Oxford, United Kingdom; ³University of British Columbia, Vancouver, BC, Canada; ⁴St. George's Hospital Medical School, London, United Kingdom; ⁵Birmingham Heartlands Hospital, Birmingham, United Kingdom; ⁶GlaxoSmithKline Global Health Outcomes, Greenford, United Kingdom 

PCO4

EPISODES OF RESPIRATORY CARE FOR MANAGED CARE PATIENTS WITH COPD: ASSESSING THE ECONOMIC BURDEN
Brown J¹, Marton JP², Friedman M¹, Chace M¹, Menzin J^1
1Boston Health Economics, Inc, Waltham, MA, USA; ²Pfizer, US Outcomes Research Group, New York, NY, USA

PCO5

ECONOMIC BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A STATE HEALTH INSURANCE PROGRAM
Joshi AV¹, Madhavan SS², Ambegaonkar AJ³, Smith M², Scott V², Dedhia H^2
1West Virginia University / Pfizer Inc, Morgantown, WV, USA; ²West Virginia University, Morgantown, WV, USA; ³Pfizer Inc, New York, NY, USA  

CHRONIC OBSTRUCTIVE PULMONARY DISEASE -Quality Of Life Studies 

PCO6
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC RESPIRATORY DISEASE
Joshi AV¹, Madhavan SS², Ambegaonkar AJ³, Smith M², Scott V², Dedhia H^2
1West Virginia University / Pfizer Inc, Morgantown, WV, USA; ²West Virginia University, Morgantown, WV, USA; ³Pfizer Inc, New York, NY, USA
 

EAR/EYE/SKIN DISEASES OR DISORDERS

EAR/EYE/SKIN DISEASES OR DISORDERS -Clinical Outcomes Studies 

PES1
PATIENTS’ PERSISTENCE AND  ADHERENCE WITH GLAUCOMA THERAPY: A LONGITUDINAL RETROSPECTIVE DATABASE ANALYSIS OF OPHTHALMIC LIPIDS
Walt J¹, Kline SEJ², Carlson A³, Trygstad GJ³, Ravelo A^1
1Allergan, Irvine, CA, USA; ²IMS Health, Plymouth Meeting, PA, USA; ³Data Intelligence Consultants LLC, Eden Prairie, MN, USA

PES2
MEDICATION ADHERENCE RATES AND DISEASE SEVERITY CHANGES IN PSORIASIS
Balkrishnan R¹, Carroll CL², Camacho F², Feldman S^2
1University of Texas School of Public Health, Houston, TX, USA; ²Wake Forest University School of Medicine, Winston-Salem, NC, USA  

PES3
PRIOR AUTHORIZATION OF TOPICAL RETINOIDS NEEDED? EVIDENCE FROM OUTPATIENT US NATIONAL PRACTICE DATA
Balkrishnan R¹, Shenolikar R¹, Sansbury JC², Feldman S^2
1University of Texas School of Public Health, Houston, TX, USA; ²Wake Forest University School of Medicine, Winston-Salem, NC, USA  

EAR/EYE/SKIN DISEASES OR DISORDERS -Cost Studies 

PES4
COST-UTILITY OF COCHLEAR IMPLANTS A SOCIETAL PERSPECTIVE ANALYSIS
Barlev A, Hay JW
University of Southern California, Los Angeles, CA, USA  

PES5

THE COST-EFFECTIVENESS OF OTOTOPICAL CIPROFLOXACIN AND DEXAMETHASONE VERSUS OTOTOPICAL OFLOXACIN FOR THE TREATMENT OF OTORRHEA IN PATIENTS WITH TYMPANOSTOMY TUBES
Roland P¹, Waycaster C^2
1University of Texas Southwestern Medical Center, Dallas, TX; ²Alcon Labs Inc, Fort Worth, TX, USA

PES6

PATIENT-REPORTED IMPACT OF AGE-RELATED MACULAR DEGENERATION
Schmier JK¹, Halpern MT¹, Covert D^2
1Exponent, Alexandria, VA, USA; ²Alcon Labs, Forth Worth, TX, USA

PES7

A COST-EFFECTIVENESS ANALYSIS OF TREATING OPEN ANGLE GLAUCOMA
Malone DC¹, Ward S², Gesser K^3
1University of Arizona, Tucson, AZ, USA; ²Royal Danish School of Pharmacy, Copenhagen, Denmark; ³The Royal Danish School of Pharmacy, Copenhagen, Denmark

PES8

ECONOMIC RESOURCES UTILIZED IN A COHORT OF PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD)
Sharma S¹, Dugar A², Bakal J¹, Brown G³, Shah G^4
1Queen's University, Kingston, ON, Canada; ²Pfizer Global Pharmaceuticals, Pfizer, Inc, New York, NY, USA; ³Wills Eye Hospital, Philadelphia, PA, Philadelphia, PA, USA; ⁴Barnes Retina Institute, St. Louis, MO, USA  

PES9
ELIGIBILITY, UTILIZATION, AND COSTS IN A CALIFORNIA MEDICAID LUPUS POPULATION
Nichol MB¹, Knight TK¹, Shi S¹, Wallace DJ², Weisman MH^3
1University of Southern California, Los Angeles, CA, USA; ²University of California, Los Angeles, CA, USA; ³Cedars-Sinai Hospital, Los Angeles, CA, USA

PES10
THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY (MAL-PDT) FOR DIFFICULT TO TREAT ACTINIC KERATOSES
Orme ME, Howard P
Heron Evidence Development, Letchworth, Herts, United Kingdom  

PES11

A COST COMPARISON OF TOPICAL 5% FLUOROURACIL VS. CRYOSURGERY FOR THE TREATMENT OF ACTINIC KERATOSIS
Knoth RL¹, Cyprien L¹, Cunningham R², Kirk M^2
1Prescription Solutions, Costa Mesa, CA, USA; ²Valeant Pharmaceuticals International, Costa Mesa, CA, USA

PES12
ESTIMATE OF DIRECT MEDICAL COSTS ASSOCIATED WITH THE USE OF CONVENTIONAL SYSTEMIC AGENTS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS
Feldman S¹, Taylor DC², Russell MW^3
1Wake Forest University School of Medicine, Winston-Salem, NC, USA; ²Innovus Research Inc, Medford, MA, USA; ³Biogen Idec, Inc, Cambridge, MA, USA  

PES14
MEDICATION AND HEALTH CARE SERVICE UTILIZATION RELATED TO DEPRESSIVE SYMPTOMS IN OLDER ADULTS WITH PSORIASIS
Kulkarni A¹, Balkrishnan R¹, Camacho F², Anderson R², Feldman S^2
1University of Texas School of Public Health, Houston, TX, USA; ²Wake Forest University School of Medicine, Winston-Salem, NC, USA  

EAR/EYE/SKIN DISEASES OR DISORDERS -Quality Of Life Studies

PES15

A COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD) WITH MONOCULAR VERSUS BILATERAL DISEASE
Dugar A¹, Sharma S², Blair J², Bakal J^2
1Pfizer Global Pharmaceuticals, Pfizer, Inc, New York, NY, USA; ²Queen's University, Kingston, ON, Canada  

PES16
VALIDATION OF A NEW SELF-ASSESSMENT QUESTIONNAIRE AND THE SKINDEX-29 QUALITY OF LIFE (QOL) INSTRUMENT FOR CHRONIC HAND DERMATITIS (CHHD): A PILOT STUDY
Fowler J¹, Ghosh A², Duh MS², Raut M³, Reynolds J², Thorn D³, Den E², Chang J^3
1University of Louisville, Lousville, KY, USA; ²Analysis Group, Boston, MA, USA; ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA  

PES17
IMPROVED HEALTH-RELATED QUALITY OF LIFE FOLLOWING SUSTAINED REDUCTIONS IN ANTI DS-DNA ANTIBODYS [ÁDSDNA AB] IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AFTER TREATMENT WITH LJP394
Crawford B¹, Strand V^2
1Mapi Values, Boston, MA, USA; ²Stanford University School of Medicine, Palo Alto, CA, USA

EARS/EYES/SKIN -Health Policy Studies

PES18
THE IMPACT OF THE SYSTEM TO MANAGE ACCUTANE-RELATED TERATOGENICITY^TM (SMART^TM) RISK MANAGEMENT PROGRAM ON ISOTRETINOIN PRESCRIBING TRENDS
Mendelsohn AB¹, Governale LA^2
1FDA & CDC, Rockville, MD, USA; ²FDA, Rockville, MD, USA

MENTAL HEALTH 

MENTAL HEALTH -Clinical Outcomes Studies  

PMH1

EFFECT OF ZIPRASIDONE INITIAL DOSING ON DISCONTINUATION IN SCHIZOPHRENIA
Harrison DJ¹, Joyce AT², Ollendorf DA², Loebel A¹, Warrington L^1
1Pfizer Inc, New York, NY, USA; ²PharMetrics Inc, Watertown, MA, USA

PMH2

GAPS IN ANTIPSYCHOTIC MEDICATION AND RISK OF HOSPITALIZATION FOR THE TREATMENT OF SCHIZOPHRENIA IN MANAGED CARE SETTINGS
Kozma C¹, Locklear J², Weiden PJ^3
1College of Pharmacy, University of South Carolina, Columbia, SC, USA; ²Janssen Pharmaceutica Products, L.P, Titusville, NJ, USA; ³SUNY Downstate Medical Center, Brooklyn, NY, USA

PMH3

FATORS ASSOCIATED WITH SECOND-GENERATION ANTIPSYCHOITC USE IN THE CALIFORNIA MEDICAID (MEDI-CAL) PATIENTS WITH SCHIZOPHRENIA
Chen L, McCombs J
University of Southern California, Los Angeles, CA, USA

PMH4

ATYPICAL ANTIPSYCHOTIC TREATMENT ADHERENCE AND PERSISTENCE IN A STATE MEDICAID PROGRAM
Zhao Z¹, Damler RM², Jackson EA^2
1Eli Lilly and Company, Indianapolis, IN, USA; ²Milliman USA, Indianapolis, IN, USA

PMH5

WITHDRAWN
 

PMH6

ANTIPSYCHOTIC TREATMENT AND DIABETES IN A PRIVATELY INSURED POPULATION
Zhao Z, Loosbrock D, Cooper L
Eli Lilly and Company, Indianapolis, IN, USA

PMH7

TREATMENT AND ECONOMIC OUTCOMES IN PEDIATRIC INPATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS
Flanders S¹, Pandina G¹, Rupnow M¹, Jensik S^2
1Janssen Pharmaceutica Products, L.P, Titusville, NJ, USA; ²Mental Health Outcomes, Inc., Lewisville, TX, USA

PMH8

SWITCHING & DISCONTINUATION OF SERTRALINE, PAROXETINE AND CITALOPRAM THERAPY
Wang J¹, Mullins CD¹, Shaya F¹, Meng F¹, Harrison D^2
1University of Maryland, Baltimore, MD, USA; ²Pfizer, Inc, New York, NY, USA

PMH9

ANALYSIS OF ANTIDEPRESSANT MEDICATION UTILIZATION AND ADHERENCE OF MANAGED CARE PATIENTS ENROLLED IN A MEDICATION ADHERENCE PROGRAM
Cockerham TR¹, Ara SB², Waugh WJ^1
1WellPoint Pharmacy Management, West Hills, CA, USA; ²Health Net, Woodland Hills, CA, USA

PMH10

PEDIATRIC ANTIDEPRESSANT PRESCRIPTION PATTERNS
Cossrow N, Von Allmen H, Henderson SC, Luce J, Yoder S, Morris LS
IMS Health, Plymouth Meeting, PA, USA

PMH11 

ANTIDEPRESSANT USE AND RISK OF SUICIDE ATTEMPT IN ADOLESCENTS WITH MAJOR DEPRESSIVE DISORDER
Valuck RJ¹, Libby AM², Sills MR², Allen RR³, Giese AA^2
1University of Colorado Health Sciences Center, Denver, CO, USA; ²University of Colorado Health Sciences Center; ³Peak Statistical Services, Inc

PMH12

THE IMPACT OF PREMATURE DISCONTINUATION OF ANTIDEPRESSANT THERAPY IN MAJOR DEPRESSIVE DISORDER
Earnshaw S¹, Krishnan A², Hogue S², Williams J^3
1RTI-Health Solutions, RTP, NC, USA; ²GlaxoSmithKline, RTP, NC, USA; ³Duke University, Durham, NC, USA

PMH13

USING PATIENT REPORTED OUTCOMES (PROS) TO DETERMINE DEPRESSION AND ANXIETY POPULATIONS IN FOUR COUNTRIES
Edmondson M, Mills D
Consumer Health Sciences, Princeton, NJ, USA

PMH14

CANADIAN NETWORK FOR BIPOLAR DISORDER (CAN-BD): FREQUENCY OF RELAPSE IN AN OBSERVATIONAL STUDY.
Yatham LN¹, Silverstone P², Baruch P³, Gorman C⁴, Leblanc J⁵, Ferrazzi S^6
1University of British Columbia, Vancouver, BC, Canada; ²University of Alberta, Edmonton, AB, Canada; ³Universite de Laval, Laval, QC, Canada; ⁴University of Calgary, Calgary, AB, Canada; ⁵Hopital du Sacre-Coeur, Montreal, QC, Canada; ⁶Janssen-Ortho Inc, Toronto, ON, Canada

PMH15

FACTORS ASSOCIATED WITH SECOND-GENERATION ANITPSYCHOTICS IN THE CALIFORNIA MEDICAID (MEDI-CAL) PATIENTS WITH BIPOLAR DISORDERS
Park J, McCombs J
University of Southern California, Los Angeles, CA, USA

PMH16

OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER: DETERMINANTS OF CHANGE IN SEVERITY OF BIPOLAR ILLNESS RATINGS
Brown E¹, Ahmed S², Schuh L², Baker RW^2
1Eli Lilly and Company, Nederland, CO, USA; ²Eli Lilly and Company, Indianapolis, IN, USA

PMH17

ANTIDEPRESSANT MONOTHERAPY AND OUTCOMES FOR PATIENTS WITH BIPOLAR DISORDER
Fu AZ
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PMH18

THE EFFECTS OF OPEN ACCESS ON DRUG THERAPY OUTCOMES FOR PATIENTS WITH BIPOLAR DISORDER IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM
Narayan S, McCombs J
University of Southern California, Los Angeles, CA, USA

PMH19

ESCITALOPRAM IN THE TREATMENT OF KLEPTOMANIA
Aboujaoude E, Gamel N, Koran L
Stanford University School of Medicine, Stanford, CA, USA

MENTAL HEALTH -Cost Studies 

PMH20
RISK OF REHOSPITALIZATION: OLANZAPINE VERSUS QUETIAPINE
Wang PF¹, Zhao Z², Cooper LM², Gaylord B¹, Gutierrez B^1
1Premier, Inc, Charlotte, NC, USA; ²Eli Lilly and Company, Indianapolis, IN, USA  

PMH21

RELATIONSHIP BETWEEN QUETIAPINE DOSE AND LEVELS OF MENTAL HEALTH RESOURCE USE AMONG PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
Gianfrancesco F¹, Wang RH², Pesa J^2
1HECON Associates, Inc, Montgomery Village, MD, USA; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PMH22

CONVENTIONAL ANTIPSYCHOTICS CAN BE COST EFFECTIVE FOR BROADLY DEFINED TREATMENT RESISTANT OR INTOLERANT SCHIZOPHRENIA
Davies L¹, Lewis S², Hay Hurst K
¹University of Manchester, Manchester, United Kingdom

PMH23

COST-EFFECTIVENESS EVALUATION OF LONG-ACTING RISPERIDONE INJECTION
Edwards N¹, Rupnow M², Pashos CL¹, Botteman MF¹, Locklear J², Diamond R^3
1Abt Associates Inc. - HERQuLES, Cambridge, MA, USA; ²Janssen Pharmaceutica Products, L.P, Titusville, NJ, USA; ³Department of Mental Health, Madison, WI, USA

PMH24

UTILIZATION ANALYSIS OF HEALTH CARE RESOURCES FOR PATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS
Liu G¹, Sun S¹, Christensen DB¹, Zhao Z^2
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²Eli Lilly and Company, Indianapolis, IN, USA

PMH25

A COMPARISON OF THE COST-EFFECTIVENESS OF OLANZAPINE FOR THE TREATMENT OF SCHIZOPHRENIA IN SELECTED NON-OECD COUNTRIES
Davey P, Price N, Lees M, Birinyi-Strachan L, Makino K, Mudge M
M-TAG Pty Ltd, Chatswood, NSW, Australia

PMH26

OUT-OF-POCKET DRUG EXPENDITURES AND PATTERNS OF DEPRESSION IN THE ELDERLY: A 5-YEAR POPULATION-BASED STUDY
Dalal M, Pickard AS, Lin SJ
University of Illinois at Chicago, Chicago, IL, USA

PMH27

DIRECT HEALTH CARE COST OF DEPRESSIVE DISORDERSIN THE UNITED STATES: A PATIENT TIME PROFILE
Birnbaum H¹, Greenberg P¹, Kessler R², Moyneur ɳ, Lowe S¹, Leong S¹, Mallett D^4
1Analysis Group, Boston, MA, USA; ²Harvard University, Boston, MA, USA; ³Analysis Group, Montreal, QC, Canada; ⁴Ingenix, New Haven, CT, USA

PMH28

COST-EFFECTIVENESS OF INTERVENTIONS TO IMPROVE PATIENT MEDICATON COMPLIANCE IN MAJOR DEPRESSIVE DISORDER
Setyawan J, Hay JW, Nichol MB
University of Southern California, Los Angeles, CA, USA

PMH29

COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS CITALOPRAM IN THE TREATMENT OF SEVERE DEPRESSION IN AUSTRIA
Hemels M EH¹, Kasper S², Walter E³, Einarson TR^4
1H. Lundbeck A/S, Paris, France; ²University of Vienna, Vienna, Austria; ³IPF - Institute for Pharmacoeconomic Research, Vienna, Austria; ⁴University of Toronto, Toronto, Canada

PMH30

WITHDRAWN

PMH31

COST AND COMORBIDITIES ASSOCIATED WITH BIPOLAR DISORDER
Parece A¹, Wu E¹, Birnbaum H¹, Greenberg P¹, Huang Z¹, Victor T², Kessler R^3
1Analysis Group/Economics, Boston, MA, USA; ²AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA; ³Harvard University, Boston, MA, USA

PMH32

COMPARISON OF BIPOLAR DISORDER-RELATED COSTS AMONG PATIENTS WITH AND WITHOUT COMORBID DIABETES
Harley C¹, Li H², L'Italien G², Hirschfeld R³, Walker A⁴, Carson W^5
1Ingenix, Eden Prairie, MN, USA; ²Bristol-Myers Squibb, Wallingford, CT, USA; ³University of Texas Medical Branch, Galveston, TX, USA; ⁴Ingenix, Auburndale, MA, USA; ⁵Otsuka America Pharmaceutical, Inc, Princeton, NJ, USA

PMH33

DRUG TREATMENT PATTERNS OF BIPOLAR DISORDER AND ASSOCIATED COSTS
Wu E¹, Birnbaum H¹, Greenberg P¹, Kessler R², Huang Z¹, Victor T³, Parece A^1
1Analysis Group / Economics, Boston, MA, USA; ²Harvard University, Boston, MA, USA; ³AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

PMH34

COST-EFFECTIVENESS OF OLANZAPINE VERSUS LITHIUM FOR THE PREVENTION OF RELAPSE IN BIPOLAR I DISORDER IN AUSTRALIA
Price N¹, Davey P¹, Mudge M¹, Fitzgerald B², Rajan N², Montgomery B^2
1M-TAG Pty Ltd, Chatswood, NSW, Australia; ²Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia

PMH35

SERVICE UTILIZATION AND COSTS FOR BIPOLAR DEPRESSION
deLay N¹, Ciaglia M², Viswanathan S^3
1Eli Lilly and Company, Indianapolis, IN, USA; ²ZS Associates, Evanston, IL, USA; ³ZS Associates, Boston, MA, USA

PMH36

THE COSTS OF POLY-PHARMACY, NON-DRUG TREATMENT, NUMBER OF DRUGS AND SWITCHING FOR BIPOLAR DISORDER
deLay N¹, Stensland MD¹, Viswanathan S², Ciaglia M^3
1Eli Lilly and Company, Indianapolis, IN, USA; ²ZS Associates, Boston, MA, USA; ³ZS Associates, Evanston, IL, USA

PMH37

COST CONSEQUENCE ASSOCIATED WITH DIFFERENT INITIAL MOOD STABILIZERS FOR NEWLY TREATED PATIENTS WITH BIPOLAR DISORDERS
Guo JJ¹, Keck PE², Jang R¹, Li H³, Carson W^4
1University of Cincinnati, Cincinnati, OH, USA; ²University of Cincinnati Medical Center, Cincinnati, OH, USA; ³Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, USA; ⁴Otsuka America Pharmaceutical, Inc, Princeton, NJ, USA

PMH38

EPILEPSY PATIENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: PREVALENCE AND COST OF CARE
Marynchenko M¹, Secnik K², Allen AJ², Birnbaum H¹, Dunn D^3
1Analysis Group, Boston, MA, USA; ²Eli Lilly and Company, Indianapolis, IN, USA; ³Indiana University Purdue University of Indianapolis, Indianapolis, IN, USA
 

PMH39 
WITHDRAWN

PMH40

COST-EFFECTIVENESS OF RITALIN^TM VERSUS ADDERALL^TM FOR FIRST-LINE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN
Narayan S¹, Hay J^2
1University of Southern California, Los Angeles, CA, USA; ²USC School of Pharmacy, Los Angeles, CA, USA

PMH41

SUICIDE ATTEMPTS BY THE ELDERLY: HOSPITAL RESOURCE USE AND COSTS
O'Brien J, Pitoniak-Morse C, Caro JJ
Caro Research Institute, Concord, MA, USA

MENTAL HEALTH -Quality Of Life/Utility/Patient Reported Outcomes Studies

PMH42

CORRELATIONS BETWEEN PSYCHOPATHOLOGY AND HEALTH RELATED QUALITY OF LIFE (HRQOL) MEASURES IN SCHIZOPHRENIA. RESULTS FROM THE SQUARE STUDY
Karokis A¹, Yfantopoulos J², Christodoulopoulou A¹, Papagiannopoulou V², Gourzis F³, Lavrentzou E⁴, Lymberaki G⁵, Yfantis A⁵, Kallinis C⁶, Gamvroula K⁷, Kafantari A⁷, Mavreas V^8
1AstraZeneca SA, Athens, Greece; ²University of Athens, Greece; ³University of Patras, Patras, Greece; ⁴University Hospital of Ioannina, Ioannina, Greece; ⁵Psychiatric Hospital of Tripoli, Tripoli, Greece; ⁶“G.Papanikolaou” General Hospital, Athens, Greece; ⁷University Psychiatric Clinic, “Papageorgiou” General Hospital, Athens, Greece; ⁸University of Ioannina, Ioannina, Greece

PMH43

DIFFERENTIAL IMPACT OF OLANZAPINE AND RISPERIDONE ON SEXUAL DYSFUNCTION AND ITS POTENTIAL IMPLICATIONS
Ascher-Svanum H, Zhu B, Faries D, Jiang Q, Kinon BJ
Eli Lilly and Company, Indianapolis, IN, USA

PMH44

REMISSION OF PSYCHOTIC SYMPTOMS AND LONG-TERM FUNCTIONAL OUTCOMES IN THE TREATMENT OF SCHIZOPHRENIA IN USUAL CARE
Ascher-Svanum H¹, Zhu B¹, Faries D¹, Jiang Q¹, Rosenheck RA^2
1Eli Lilly and Company, Indianapolis, IN, USA; ²Yale University School of Medicine, West Haven, CT, USA

PMH45

MAPPING UTILITY SCORES FROM THE EQ-5D AND SF-6D ONTO THE SCHIZOPHRENIA QUALITY OF LIFE SCALE
Clayson DJ¹, Briggs A², Sculpher M³, De Hert M^4
1Oxford Outcomes Ltd, Oxford, Oxon, United Kingdom; ²University of Oxford, Oxford, United Kingdom; ³University of York, York, North Yorkshire, United Kingdom; ⁴University Centrum V.Z.W, Centrum, Belgium

PMH46

IMPROVEMENTS IN COGNITIVE DEFICITS ARE ASSOCIATED WITH IMPROVED FUNCTIONAL OUTCOMES: RESULTS FROM A LONGITUDINAL OBSERVATIONAL STUDY OF SCHIZOPHRENIA PATIENTS
Ascher-Svanum H, Zhu B, Faries D, Jiang Q, Shi L
Eli Lilly and Company, Indianapolis, IN, USA

PMH47

WEIGHT GAIN AND IMPROVEMENT IN PSYCHOPATHOLOGY DURING TREATMENT OF SCHIZOPHRENIA WITH ANTIPSYCHOTICS AND WITH PLACEBO
Ascher-Svanum H, Stensland MD, Kinon BJ, Tollefson GD
Eli Lilly and Company, Indianapolis, IN, USA

PMH48

ASSESSMENT OF THE IMPACT OF QUETIAPINE TREATMENT ON PSYCHOPATHOLOGY, HEALTH RELATED QUALITY OF LIFE AND DISABILITY IN PATIENTS WITH SCHIZOPHRENIA IN GREECE. THE SQUARE STUDY
Christodoulopoulou A¹, Yfantopoulos J², Karokis A¹, Papagiannopoulou V², Karavatos A³, Gourzis F⁴, Mouzas O⁵, Panagoutsos P⁶, Tzanakaki M⁷, Stathakis I⁸, Mavreas V^9
1AstraZeneca SA, Athens, Greece; ²University of Athens, Athens, Greece; ³University Psychiatric Clinic, “Papageorgiou” General Hospital, Athens, Greece; ⁴University of Patras, Patras, Greece; ⁵University Hospital of Larissa, Larissa, Greece; ⁶Psychiatric Hospital of Tripoli, Tripoli, Greece; ⁷Psychiatric Hospital of Hania, Hania, Greece; ⁸“G.Papanikolaou” General Hospital, Athens, Greece; ⁹University of Ioannina, Ioannina, Greece

PMH49

USING CLIENT AND STAFF STRUCTURED INPUT IN FORMATTING THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP) SURVEY
Barr J, Schumacher G, Ohman SM, Quimby C
Northeastern University, Boston, MA, USA

PMH50

THE ROLE OF ANTIPARKINSONIAN AGENTS IN SELF-REPORTED COGNITIVE IMPAIRMENT AND AKATHISIA DURING THE LONG-TERM TREATMENT OF SCHIZOPHRENIA
Ascher-Svanum H, Zhu B, Faries D, Jiang Q
Eli Lilly and Company, Indianapolis, IN, USA

PMH51
WITHDRAWN

PMH52

IMPROVEMENT IN QUALITY-OF-LIFE WITH RISPERIDONE AUGMENTATION IN TREATMENT-RESISTANT DEPRESSION
Walling D¹, Rupnow M², Canuso C², Gharabawi G², Turkoz I², Rapaport M^3
1CNS Network, Garden Grove, CA, USA; ²Janssen Pharmaceutica Products, L.P, Titusville, NJ, USA; ³Cedars-Sinai Medical Center, Los Angeles, CA, USA  

PMH53
HOSPITALIZATION RATES DURING COMBINATION THERAPY WITH ATYPICAL ANTIPSYCHOTICS IN BIPOLAR DISORDER
Lazarus A¹, Lage MJ², Pesa JA^2
1AstraZeneca, Wilmington, DE, USA; ²AstraZeneca LP, Wilmington, DE, USA

PMH54

WORK LOSS ASSOCIATED WITH BIPOLAR DISORDER
Sasane R¹, de Lissovoy G², Matza LS², Mauskopf JA³, Pesa JA^1
1AstraZeneca LP, Wilmington, DE, USA; ²MEDTAP International, Bethesda, MD, USA; ³Research Triangle Institute, Research Triangle Park, NC, USA

PMH55

CHILD HEALTH ILLNESS PROFILE AS A QUALITY OF LIFE MEASURE OF CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
Secnik K¹, Matza L², Mannix S^3
1Eli Lilly and Company, Indianapolis, IN, USA; ²MEDTAP International, Bethesda, MD, USA, USA; ³MEDTAP International, Inc, Bethesda, MD, USA

MENTAL HEALTH -Health Policy Studies 

PMH56
MENTAL HEALTH SERVICES AND DRUG UTILIZATION PATTERNS FOR STUDENTS WITH MENTAL ILLNESSES IN SCHOOL-BASED HEALTH CENTERS
Guo JJ¹, Jang R¹, Cluxton RJ¹, Keller K^2
1University of Cincinnati, Cincinnati, OH, USA; ²Health Foundation of Greater Cincinnati, Cincinnati, OH, USA

PMH57

THE EFFECT OF BEHAVIORAL CARVE-OUTS ON PHARMACEUTICAL USE AND EXPENDITURES
Mark TL, Coffey R
Medstat, Washington, DC, USA

PMH58

THE RELATIONSHIP BETWEEN MENTAL DISTRESS, HEALTH RISKS AND HEALTH CARE COSTS FROM THE MANAGED CARE HEALTH RISK ASSESSMENT DATABASE
Manocchia M¹, Brown J², Finkelstein J^3
1Blue Cross and Blue Shield of Rhode Island, Providence, RI, USA; ²Boston Health Economics, Inc., Waltham, MA, USA; ³Brown University, Providence, RI, USA

PMH59

ANTIPSYCHOTIC ADHERENCE AMONG CENTRAL TEXAS VETERANS
Yang M¹, Barner J¹, Worchel J^2
1University of Texas at Austin, Austin, TX, USA; ²Veterans Administration, Austin, TX, USA  

PMH60
ANALYSIS OF LONGITUDINAL CLAIMS DATA TO EXAMINE FIRST AND SECOND-LINE USE OF PEMOLINE (CYLERT®)
Morrato E¹, Staffa J^2
1Johns Hopkins University Bloomberg School of Public Health (FDA student project), Baltimore, MD, USA; ²Food and Drug Administration, Rockville, MD, USA  

PMH61
TRENDS IN ANTIPSYCHOTIC PRESCRIBING TO CHILDREN AND ADOLESCENTS: 1996 TO 2001
Patel NC¹, Crismon ML¹, Hoagwood K², Johnsrud M¹, Rascati K¹, Wilson JP^1
1The University of Texas at Austin, Austin, TX, USA; ²Columbia University, New York, NY, USA

PMH62
HOSPITAL UTILIZATION FOLLOWING AN OPEN ACCESS POLICY FOR ATYPICAL ANTIPSYCHOTIC MEDICATIONS FOR PATIENTS WITH SCHIZOPHRENIA
O'Reilly DJ, Parfrey PS
Memorial University of Newfoundland, St. John's, NF, Canada  

PMH63

TREND AND GEOGRAPHIC VARIATIONS IN THE LENGTH OF STAY FOR SCHIZOPHRENIA IN THE UNITED STATES
Sun SX¹, Liu G¹, Luo X², Fu AZ^1
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ²Duke University Medical Center, Durham, NC, USA  

PMH64
MISDIAGNOSIS OF BIPOLAR DISORDER AS UNIPOLAR DEPRESSION:
Stensland MD¹, deLay N¹, Ciaglia M², Viswanathan S^3
1Eli Lilly and Company, Indianapolis, IN, USA; ²ZS Associates, Evanston, IL, USA; ³ZS Associates, Boston, MA, USA  

PMH65

SECOND SSRIS SWITCHING AND DISCONTINUATION AFTER FLUOXETINE INITIAL THERAPY
Shaya F¹, Mullins CD¹, Meng F¹, Wang J¹, Harrison D^2
1University of Maryland, Baltimore, MD, USA; ²Pfizer, Inc, New York, NY, USA

PMH66

COMPARISON OF FIRST REFILL RATES AMONG BRANDED SSRI USERS
Mullins CD¹, Shaya F¹, Meng F¹, Wang J¹, Bron M^2
1University of Maryland, Baltimore, MD, USA; ²Pfizer, Inc, New York, NY, USA

PMH67

DEPRESSION DIAGNOSIS IN PRIMARY CARE VISITS NOT FOR MENTAL HEALTH REASONS
Singer ME, Propper VH
Case Western Reserve University, Cleveland, OH, USA  

PMH68
TRENDS IN PHARMACOLOGIC TREATMENT FOR PATIENTS WITH BIPOLAR: 1992-2002
Cooper L, Zhao Z, Zhu B
Eli Lilly and Company, Indianapolis, IN, USA  

PMH69

PATTERNS OF PHARMACOLOGIC TREATMENT FOR PATIENTS WITH BIPOLAR DISORDER
Zhu B, Zhao Z, Cooper L
Eli Lilly and Company, Indianapolis, IN, USA

PMH70

PHARMACOLOGIC TREATMENT PATTERNS FOR BIPOLAR DISORDER
deLay N¹, Stensland MD¹, Viswanathan S², Ciaglia M^3
1Eli Lilly and Company, Indianapolis, IN, USA; ²ZS Associates, Boston, MA, USA; ³ZS Associates, Evanston, IL, USA

PMH71

WHEN BIPOLAR DISORDER IS BEING IDENTIFIED: PHASE OF DISORDER, PROVIDER SPECIALTY, FACILITY TYPE, AND RESOURCE UTILIZATION SURROUNDING THE INITIAL BIPOLAR DIAGNOSIS IN CLINICAL PRACTICE.
Stensland MD¹, deLay N¹, Viswanathan S², Ciaglia M^3
1Eli Lilly and Company, Indianapolis, IN, USA; ²ZS Associates, Boston, MA, USA; ³ZS Associates, Evanston, IL, USA

PMH72

MEDICATION PRESCRIBING PATTERNS FOR PATIENTS WITH BIPOLAR DEPRESSION
deLay N¹, Viswanathan S², Ciaglia M³, Stensland MD¹, Zhao Z¹, Vedarajan G^3
1Eli Lilly and Company, Indianapolis, IN, USA; ²ZS Associates, Boston, MA, USA; ³ZS Associates, Evanston, IL, USA  

MENTAL HEALTH -Methods 

PMH73
DEPRESSION IN THE GENERAL POPULATION AND AFTER STROKE: A PSYCHOMETRIC COMPARISON USING THE CES-D SCALE
Pickard AS¹, Dalal M¹, Bushnell DM^2
1University of Illinois at Chicago, Chicago, IL, USA; ²Health Research Associates, Inc, Mountlake Terrace, WA, USA  

PMH74

COMPARING PSYCHOMETRIC PROPE